Arbutus Biopharma Corp (ABUS) earnings · P/E 5.4, rev $180.1M
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
This ABUS earnings page is the cached print — revenue, income, and the latest exhibit — not a live call transcript.
Latest reported ABUS revenue for 2026-06-30 was $180.1M. Net income was $164.6M. Revenue was up 0.6% from 2026-03-31 to 2026-06-30. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
When the next ABUS 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was up 0.6% from 2026-03-31 to 2026-06-30. An earnings headline that ignores that move is noise.
Not investment advice. Full ABUS research stays on the stock page; the tape stays on the quote page.
Not investment advice.